Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > Nanobiotix completes patient inclusion for Phase II/III trial of NBTXR3 in soft tissue sarcoma

Abstract:
NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that it has completed patient inclusion for the Phase II/III trial (Act.In.Sarc) of its lead product candidate, NBTXR3, in soft tissue sarcoma. The last patients are expected to start their treatment in two to three weeks.

Nanobiotix completes patient inclusion for Phase II/III trial of NBTXR3 in soft tissue sarcoma

Paris, France and Cambridge, MA | Posted on October 23rd, 2017

Elsa Borghi, Nanobiotix’s Chief Medical Officer commented: “We are pleased to have reached this important milestone in Nanobiotix’s soft tissue sarcoma study, and we look forward to reporting our first data next year.”

The pivotal international Phase II/III study in soft tissue sarcoma was launched in Europe and Asia in October 2014 and aims to evaluate the safety and the efficacy of NBTXR3, a first-in-class radio-enhancer that could potentially target most solid tumors. The Phase II/III study is a prospective, randomized, multi-center, open label and active controlled two-arm study of 156 patients with locally advanced soft tissue sarcoma.

The trial’s primary endpoint is the complete pathological response rate. The secondary endpoints are the objective response rate (ORR) by imaging (MRI); the evaluation of the safety profile in terms of clinical and laboratory adverse events; the tumor volume changes; the resection margins and the limb amputation rate. Furthermore, an exploratory analysis of the progression free survival is planned once the follow-up period has been completed for all treated patients.

Nanobiotix expects to present the results of its Phase II/III trial in soft tissue sarcoma in the first half of 2018.

For more information about the study: Clinical trial.gov and http://www.actinsarc.com/ .

####

About Nanobiotix
Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a late clinical-stage nanomedicine company pioneering novel approaches for the treatment of cancer. The Company’s first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy with a view to providing a new, more efficient treatment for cancer patients.
NanoXray products are compatible with current radiotherapy treatments and are meant to treat potentially a wide variety of solid tumors including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, etc., via multiple routes of administration.

NBTXR3 is being evaluated in: soft tissue sarcoma (STS), head and neck cancers, prostate cancer, and liver cancers (primary and metastases). Additionally, head and neck cancer and rectal cancer trials led by Nanobiotix’s Taiwanese partner, PharmaEngine, are underway in the Asia Pacific region. The Company filed in August 2016 for market approval (CE Marking) in Europe for its lead product NBTXR3.

In 2016 the Company started a new preclinical research program in Immuno-oncology with its lead product NBTXR3, which could have the potential to bring a new dimension to cancer immunotherapies.

Nanobiotix is listed on the regulated market of Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP). The Company’s Headquarters is based in Paris, France, with a U.S. affiliate in Cambridge, MA.

Disclaimer

This press release contains certain forward-looking statements concerning Nanobiotix and its business. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of Nanobiotix filed with the French Financial Markets Authority (Autorité des Marchés Financiers) under number D.17-0470 on April 28, 2017 (a copy of which is available on www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.

This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Nanobiotix shares in any country. At the moment NBTXR3 does not bear a CE mark and is not permitted to be placed on the market or put into service until NBTXR3 has obtained a CE mark.

For more information, please click here

Contacts:
Nanobiotix

Sarah Gaubert
Director, Communications & Public Affairs
+33 (0)1 40 26 07 55
/



Noël Kurdi
Director, Investor Relations
+1 (646) 241-4400
/
Media relations

France – Springbok Consultants
Marina Rosoff
+33 (0)6 71 58 00 34



United States – RooneyPartners
Marion Janic
+1 (212) 223-4017

Copyright © Nanobiotix

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Efficiently processing high-quality periodic nanostructures with ultrafast laser July 1st, 2022

Photonic synapses with low power consumption and high sensitivity are expected to integrate sensing-memory-preprocessing capabilities July 1st, 2022

New protocol for assessing the safety of nanomaterials July 1st, 2022

Boron nitride nanotube fibers get real: Rice lab creates first heat-tolerant, stable fibers from wet-spinning process June 24th, 2022

Govt.-Legislation/Regulation/Funding/Policy

Solving the solar energy storage problem with rechargeable batteries that can convert and store energy at once June 24th, 2022

Boron nitride nanotube fibers get real: Rice lab creates first heat-tolerant, stable fibers from wet-spinning process June 24th, 2022

UBCO researchers change the game when it comes to activity tracking: Flexible, highly sensitive motion device created by extrusion printing June 17th, 2022

University of Illinois Chicago joins Brookhaven Lab's Quantum Center June 10th, 2022

Nanomedicine

From outside to inside: A rapid and precise total assessment method for cells: Researchers at Nara Institute of Science and Technology show that using four frequencies of applied voltage can improve the measurement of cell size and shape during impedance cytometry, enabling to en June 24th, 2022

New technology helps reveal inner workings of human genome June 24th, 2022

Disinfectant mechanism of nano-sized electrostatic atomized water particles on SARS-CoV-2: Nano-sized electrostatic atomized water particles destroy SARS-CoV-2 envelope, protein, and RNA, thereby impairing the virus’s ability to bind to host cells June 17th, 2022

New nano-gel to protect children receiving chemotherapy from hearing loss June 17th, 2022

Announcements

Efficiently processing high-quality periodic nanostructures with ultrafast laser July 1st, 2022

Photonic synapses with low power consumption and high sensitivity are expected to integrate sensing-memory-preprocessing capabilities July 1st, 2022

New protocol for assessing the safety of nanomaterials July 1st, 2022

Boron nitride nanotube fibers get real: Rice lab creates first heat-tolerant, stable fibers from wet-spinning process June 24th, 2022

Nanobiotechnology

From outside to inside: A rapid and precise total assessment method for cells: Researchers at Nara Institute of Science and Technology show that using four frequencies of applied voltage can improve the measurement of cell size and shape during impedance cytometry, enabling to en June 24th, 2022

New technology helps reveal inner workings of human genome June 24th, 2022

Disinfectant mechanism of nano-sized electrostatic atomized water particles on SARS-CoV-2: Nano-sized electrostatic atomized water particles destroy SARS-CoV-2 envelope, protein, and RNA, thereby impairing the virus’s ability to bind to host cells June 17th, 2022

New nano-gel to protect children receiving chemotherapy from hearing loss June 17th, 2022

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project